A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).
NCT ID: NCT05507229
Last Updated: 2022-08-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE3
Total Enrollment
1800 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-02-22
Study Completion Date
2022-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the noninferiority of immunogenicity and safety of single strain oral cholera vaccine Hillchol® (BBV131) to the comparator vaccine Shanchol™ along with lot-to-lot consistency of Hillchol® (BBV131).
Study Population: A total of 1800 participants will be enrolled in three descending age groups (Group I- \>18, Group II: \> 5 to \<18 and Group-III: \>1 to \<5) in 3(1350):1(450) ratio. In each group 600 participants will be enrolled and among 600 participants 450 participants will receive any lot of Hillchol® (BBV131) and 150 participants will receive Shanchol™.
DSMB and report:After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group I, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group I and starting recruitment of participants for group II.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group II, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group II and starting recruitment of participants for group III.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131): 10-Lot-I, 10-Lot-II, 10-Lot-III and 10-shanchol) in the Group III, safety data of these subjects will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group III.
A Final report will be generated, based on the safety and immunogenicity of the oral cholera vaccine (Hillchol®) will be notified to the Data safety monitoring board and Central Drugs Standard Control Organization (CDSCO), India.
Study Population: A total of 1800 participants will be enrolled in three descending age groups (Group I- \>18, Group II: \> 5 to \<18 and Group-III: \>1 to \<5) in 3(1350):1(450) ratio. In each group 600 participants will be enrolled and among 600 participants 450 participants will receive any lot of Hillchol® (BBV131) and 150 participants will receive Shanchol™.
DSMB and report:After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group I, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group I and starting recruitment of participants for group II.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group II, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group II and starting recruitment of participants for group III.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131): 10-Lot-I, 10-Lot-II, 10-Lot-III and 10-shanchol) in the Group III, safety data of these subjects will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group III.
A Final report will be generated, based on the safety and immunogenicity of the oral cholera vaccine (Hillchol®) will be notified to the Data safety monitoring board and Central Drugs Standard Control Organization (CDSCO), India.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
NCT05732766
Cholera
UNKNOWN
PHASE3
Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™
NCT04760236
Cholera
COMPLETED
PHASE3
A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children
NCT00760825
Vibrio Cholerae
COMPLETED
PHASE4
Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine
NCT02823899
Cholera
COMPLETED
PHASE1/PHASE2
Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine
NCT01508507
Cholera
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A Phase III randomized, modified double-blind, multi-centric, comparative study, to evaluate the noninferiority of immunogenicity and safety of single strain oral cholera vaccine Hillchol® (BBV131) to the comparator vaccine Shanchol™ along with lot-to-lot consistency of Hillchol® (BBV131)
Study Population: A total of 1800 participants will be enrolled in three descending age groups (Group I- \>18, Group II: \> 5 to \<18 and Group-III: \>1 to \<5) in 3(1350):1(450) ratio. In each group 600 participants will be enrolled and among 600 participants 450 participants will receive any lot of Hillchol® (BBV131) and 150 participants will receive Shanchol™.
Study objectives:
Primary Objectives:
1\) To demonstrate non-inferiority of immunogenicity Hillchol®(BBV131) to that of Shanchol by comparing the seroconversion rate (defined as '4 fold rise in vibriocidal antibody titer compared to baseline') upon administration of 2 doses of Hillchol®(BBV131) or Shanchol, across all age groups. Secondary
Secondary objectives:
1. To evaluate and compare the immunogenicity of Hillchol®(BBV131) with that of Shanchol across all age groups, by comparing the geometric mean titers (GMT) of vibriocidal antibodies in participants receiving Hillchol®(BBV131) and ShancholTM.
2. To evaluate and compare the frequency and severity of all solicited and unsolicited adverse events upon administration of two doses of Hillchol®(BBV131) or ShancholTM, among all three age groups.
Exploratory Objectives:
1)To demonstrate the consistency of immunogenicity for 3 consecutive lots of Hillchol®(BBV131) (lot-to-lot consistency) across all age groups, by comparing the GMT of vibriocidal antibodies in participants receiving doses from each vaccine lot of Hillchol®(BBV131).
Study Endpoints/Outcome:
1. The proportion of participants achieving seroconversion against Ogawa serotype, 14 days after 2 doses of test or comparator vaccine.
2. The proportion of participants achieving seroconversion against Inaba serotype, 14 days after 2 doses of test or comparator vaccine.
3. Geometric Mean Titers (GMT) of anti-Ogawa antibodies two weeks after 2 doses of Test or comparator vaccine
4. GMT of anti-Inaba antibodies two weeks after 2 doses of Test or comparator vaccine.
5. Immediate reaction: Within 30 mins of administration of each dose.
6. Incidence, intensity, the causality of all solicited adverse events during the 7-day follow-up period after each dose.
7. Incidence, intensity, the causality of unsolicited adverse events during the 14-day follow-up period after each dose.
8. Incidence, intensity, the causality of all adverse events and Serious Adverse Events (SAEs) during the entire study period.
9. The proportion of participants achieving seroconversion against Ogawa and Inaba serotype, 14 days after 2 doses for each consecutive batch of Hillchol®(BBV131).
Sero-conversion is defined as a 4-fold rise above the baseline 14 days post-second dose Geometric mean of vibriocidal antibody titers to be calculated.
Study design:
In this study, a total sample size of 1800 participants will be enrolled in three groups in age descending manner and administered with Hillchol®(BBV131) or Shanchol™.
A) Group-I (Age :\> 18): In this group, a total of 600 participants aged \>18 will be enrolled and randomly assigned into 1:1:1:1 ratio to receive either any three lots of Hillchol®(BBV131) (150: Lot-I, 150: Lot-II and 150: Lot-III) or Shanchol® (150) on day 0 and 14.
After completion of 7 days post, 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I, 10-Lot-II,10-Lot-III and 10-shanchol) in the Group I, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, the study will progress by recruiting remaining 560 participants in the group I and starting recruitment of participants for group II.
B) Group-II (Age: \>5 to \<18): In this group, a total of 600 participants aged \>5 to \<18 will be enrolled and randomly assigned into 1:1:1:1 ratio to receive either any three lots of Hillchol® (BBV131)(150: Lot-I, 150: Lot-II and 150: Lot-III) or Shanchol®(150)on day 0 and 14.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group II, safety data of these participants will be reviewed by the Data Safety Monitoring Board (DSMB) and based on their recommendation, the study will progress by recruiting remaining 560 participants in the group II and starting recruitment of participants for group III.
C) Group-III (Age: \>1 to \<5): In this group, a total of 600 participants aged \>1 to \<5 will be enrolled and randomly assigned into 1:1:1:1 ratio to receive either any three lots of Hillchol® (BBV131) (150: Lot-I, 150: Lot-II and 150: Lot-III) or Shanchol® (150) on day 0 and 14.
After completion of 7 days post, 1st dose for 40 participants (Hillchol (BBV131): 10-Lot-I, 10-Lot-II, 10-Lot-III and 10-shanchol) in the Group III, the safety data of these subjects will be reviewed by the Data Safety Monitoring Board (DSMB) and based on their recommendation, the study will progress by recruiting the remaining 560 participants in the group III.
Eligibility Criteria:
Inclusion Criteria
1. Participants /Legally acceptable representatives who have ability to provide written informed consent.
2. Participants of either gender of age \> 1 year.
3. Expressed interest and availability to fulfil the study requirements.
1. Willing to receive two dosesof the vaccine at the specific study site.
2. Willing to be contacted on the phone to assess adverse events and for study reminders.
4. Agrees not to participate in another clinical study at any time during the study period.
Exclusion
1. Any history of anaphylaxis in relation to vaccination.
2. Participant with Immune function disorders including immunodeficiency diseases, or taking immunosuppressive/cytotoxic agents.
3. An individual thought to have difficulty participating in the study due to severe chronic diseases, based on the judgment of the investigator.
4. Participants with 38℃ or higher body temperature measured within 24 hours or at the time of investigational product dosing.
5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study initiation
6. Diarrhea or administration of anti-diarrheal drugs or antibiotics to treat diarrhea within 1 week prior to study initiation.
7. Other vaccination within 4week prior to study initiation.
8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation.
9. Participation in another clinical trial.
10. History of cholera vaccinations or history of cholera diarrhea.
11. Pregnancy, lactation or willingness/intention to become pregnant during the study.
12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
13. History of any psychiatric condition likely to affect participation in the study.
14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
15. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the study or would render the subject unable to comply with the protocol
Study Procedure:
Visit 1: Baseline (Day 0) If eligible, study participants will attend the OPD for physical, general examination. Blood samples will be drawn prior to vaccination. A study vaccine will be administered. Following vaccination, participants will remain at the study site for at least 30 minutes to record any adverse event. Diary cards will be distributed to all the participants to record the adverse events after vaccination.
Day 1-7: The study participants will be telephonically followed up by the site for the first 7 days to know their current health status.
Visit 2: (Day 14+2) Study participants will return to the OPD for physical, general examination. Blood samples will be collected for immunogenicity test. A study vaccine will be administered. Following vaccination, participants will remain at the study site for at least 30 minutes to record any adverse event. Diary cards will be distributed to all the participants to record the adverse events after vaccination. Day 15-21: The study participants will be telephonically followed up by the site for the first 7 days to know their current health status.
Visit 3: (Day 28+2) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity.
Visit 4: (Day 56±7) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity.
Visit 5: (Day 90±7) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity.
Visit 6: (Day 180±7) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity. Safety Monitoring: Subjects will be observed for 30 minutes after vaccination for immediate adverse events.
Active surveillance will be conducted for all participants for 7 days and 14 days after each dose of vaccine to ascertain information on solicited adverse events and unsolicited adverse events ("Reactogenicity").
Unscheduled visits:
If any subject develops any adverse or serious adverse event or concerned about his/her health, they will be advised to visit the study site during the study follow-up period. All unscheduled visits and details of adverse events will be documented in the source document. Concomitant medications, if any, will also be recorded.
DSMB \& Final report:
DSMB and report:After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group I, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group I and starting recruitment of participants for group II.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group II, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group II and starting recruitment of participants for group III.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131): 10-Lot-I, 10-Lot-II, 10-Lot-III and 10-shanchol) in the Group III, safety data of these subjects will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group III.
A Final report will be generated, based on the safety and immunogenicity of the oral cholera vaccine (Hillchol®) will be notified to the Data safety monitoring board and Central Drugs Standard Control Organization (CDSCO), India.
Study Population: A total of 1800 participants will be enrolled in three descending age groups (Group I- \>18, Group II: \> 5 to \<18 and Group-III: \>1 to \<5) in 3(1350):1(450) ratio. In each group 600 participants will be enrolled and among 600 participants 450 participants will receive any lot of Hillchol® (BBV131) and 150 participants will receive Shanchol™.
Study objectives:
Primary Objectives:
1\) To demonstrate non-inferiority of immunogenicity Hillchol®(BBV131) to that of Shanchol by comparing the seroconversion rate (defined as '4 fold rise in vibriocidal antibody titer compared to baseline') upon administration of 2 doses of Hillchol®(BBV131) or Shanchol, across all age groups. Secondary
Secondary objectives:
1. To evaluate and compare the immunogenicity of Hillchol®(BBV131) with that of Shanchol across all age groups, by comparing the geometric mean titers (GMT) of vibriocidal antibodies in participants receiving Hillchol®(BBV131) and ShancholTM.
2. To evaluate and compare the frequency and severity of all solicited and unsolicited adverse events upon administration of two doses of Hillchol®(BBV131) or ShancholTM, among all three age groups.
Exploratory Objectives:
1)To demonstrate the consistency of immunogenicity for 3 consecutive lots of Hillchol®(BBV131) (lot-to-lot consistency) across all age groups, by comparing the GMT of vibriocidal antibodies in participants receiving doses from each vaccine lot of Hillchol®(BBV131).
Study Endpoints/Outcome:
1. The proportion of participants achieving seroconversion against Ogawa serotype, 14 days after 2 doses of test or comparator vaccine.
2. The proportion of participants achieving seroconversion against Inaba serotype, 14 days after 2 doses of test or comparator vaccine.
3. Geometric Mean Titers (GMT) of anti-Ogawa antibodies two weeks after 2 doses of Test or comparator vaccine
4. GMT of anti-Inaba antibodies two weeks after 2 doses of Test or comparator vaccine.
5. Immediate reaction: Within 30 mins of administration of each dose.
6. Incidence, intensity, the causality of all solicited adverse events during the 7-day follow-up period after each dose.
7. Incidence, intensity, the causality of unsolicited adverse events during the 14-day follow-up period after each dose.
8. Incidence, intensity, the causality of all adverse events and Serious Adverse Events (SAEs) during the entire study period.
9. The proportion of participants achieving seroconversion against Ogawa and Inaba serotype, 14 days after 2 doses for each consecutive batch of Hillchol®(BBV131).
Sero-conversion is defined as a 4-fold rise above the baseline 14 days post-second dose Geometric mean of vibriocidal antibody titers to be calculated.
Study design:
In this study, a total sample size of 1800 participants will be enrolled in three groups in age descending manner and administered with Hillchol®(BBV131) or Shanchol™.
A) Group-I (Age :\> 18): In this group, a total of 600 participants aged \>18 will be enrolled and randomly assigned into 1:1:1:1 ratio to receive either any three lots of Hillchol®(BBV131) (150: Lot-I, 150: Lot-II and 150: Lot-III) or Shanchol® (150) on day 0 and 14.
After completion of 7 days post, 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I, 10-Lot-II,10-Lot-III and 10-shanchol) in the Group I, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, the study will progress by recruiting remaining 560 participants in the group I and starting recruitment of participants for group II.
B) Group-II (Age: \>5 to \<18): In this group, a total of 600 participants aged \>5 to \<18 will be enrolled and randomly assigned into 1:1:1:1 ratio to receive either any three lots of Hillchol® (BBV131)(150: Lot-I, 150: Lot-II and 150: Lot-III) or Shanchol®(150)on day 0 and 14.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group II, safety data of these participants will be reviewed by the Data Safety Monitoring Board (DSMB) and based on their recommendation, the study will progress by recruiting remaining 560 participants in the group II and starting recruitment of participants for group III.
C) Group-III (Age: \>1 to \<5): In this group, a total of 600 participants aged \>1 to \<5 will be enrolled and randomly assigned into 1:1:1:1 ratio to receive either any three lots of Hillchol® (BBV131) (150: Lot-I, 150: Lot-II and 150: Lot-III) or Shanchol® (150) on day 0 and 14.
After completion of 7 days post, 1st dose for 40 participants (Hillchol (BBV131): 10-Lot-I, 10-Lot-II, 10-Lot-III and 10-shanchol) in the Group III, the safety data of these subjects will be reviewed by the Data Safety Monitoring Board (DSMB) and based on their recommendation, the study will progress by recruiting the remaining 560 participants in the group III.
Eligibility Criteria:
Inclusion Criteria
1. Participants /Legally acceptable representatives who have ability to provide written informed consent.
2. Participants of either gender of age \> 1 year.
3. Expressed interest and availability to fulfil the study requirements.
1. Willing to receive two dosesof the vaccine at the specific study site.
2. Willing to be contacted on the phone to assess adverse events and for study reminders.
4. Agrees not to participate in another clinical study at any time during the study period.
Exclusion
1. Any history of anaphylaxis in relation to vaccination.
2. Participant with Immune function disorders including immunodeficiency diseases, or taking immunosuppressive/cytotoxic agents.
3. An individual thought to have difficulty participating in the study due to severe chronic diseases, based on the judgment of the investigator.
4. Participants with 38℃ or higher body temperature measured within 24 hours or at the time of investigational product dosing.
5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study initiation
6. Diarrhea or administration of anti-diarrheal drugs or antibiotics to treat diarrhea within 1 week prior to study initiation.
7. Other vaccination within 4week prior to study initiation.
8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation.
9. Participation in another clinical trial.
10. History of cholera vaccinations or history of cholera diarrhea.
11. Pregnancy, lactation or willingness/intention to become pregnant during the study.
12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
13. History of any psychiatric condition likely to affect participation in the study.
14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
15. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the study or would render the subject unable to comply with the protocol
Study Procedure:
Visit 1: Baseline (Day 0) If eligible, study participants will attend the OPD for physical, general examination. Blood samples will be drawn prior to vaccination. A study vaccine will be administered. Following vaccination, participants will remain at the study site for at least 30 minutes to record any adverse event. Diary cards will be distributed to all the participants to record the adverse events after vaccination.
Day 1-7: The study participants will be telephonically followed up by the site for the first 7 days to know their current health status.
Visit 2: (Day 14+2) Study participants will return to the OPD for physical, general examination. Blood samples will be collected for immunogenicity test. A study vaccine will be administered. Following vaccination, participants will remain at the study site for at least 30 minutes to record any adverse event. Diary cards will be distributed to all the participants to record the adverse events after vaccination. Day 15-21: The study participants will be telephonically followed up by the site for the first 7 days to know their current health status.
Visit 3: (Day 28+2) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity.
Visit 4: (Day 56±7) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity.
Visit 5: (Day 90±7) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity.
Visit 6: (Day 180±7) Study participants will return to the OPD for physical, general examination. Blood samples will be withdrawn to assess immunogenicity. Safety Monitoring: Subjects will be observed for 30 minutes after vaccination for immediate adverse events.
Active surveillance will be conducted for all participants for 7 days and 14 days after each dose of vaccine to ascertain information on solicited adverse events and unsolicited adverse events ("Reactogenicity").
Unscheduled visits:
If any subject develops any adverse or serious adverse event or concerned about his/her health, they will be advised to visit the study site during the study follow-up period. All unscheduled visits and details of adverse events will be documented in the source document. Concomitant medications, if any, will also be recorded.
DSMB \& Final report:
DSMB and report:After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group I, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group I and starting recruitment of participants for group II.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131):10-Lot-I,10-Lot-II,10-Lot-III and 10-shanchol) in the Group II, safety data of these participants will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group II and starting recruitment of participants for group III.
After completion of 7 days post 1st dose for 40 participants (Hillchol (BBV131): 10-Lot-I, 10-Lot-II, 10-Lot-III and 10-shanchol) in the Group III, safety data of these subjects will be reviewed by Data Safety Monitoring Board (DSMB) and based on their recommendation, study will progress by recruiting remaining 560 participants in the group III.
A Final report will be generated, based on the safety and immunogenicity of the oral cholera vaccine (Hillchol®) will be notified to the Data safety monitoring board and Central Drugs Standard Control Organization (CDSCO), India.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cholera
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Double blind Study
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Hillchol®(BBV131) vaccine - (Lot-I ) administered to 450 subjects on day 0 and 14.
Group Type
EXPERIMENTAL
Hillchol vaccine
Intervention Type
BIOLOGICAL
HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Arm 2
Hillchol®(BBV131) vaccine - (Lot-II) administered to 450 subjects on day 0 and 14.
Group Type
EXPERIMENTAL
Hillchol vaccine
Intervention Type
BIOLOGICAL
HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Arm 3
Hillchol®(BBV131) vaccine - (Lot-III ) administered to 450 subjects on day 0 and 14 .
Group Type
EXPERIMENTAL
Hillchol vaccine
Intervention Type
BIOLOGICAL
HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Arm 4
Shanchol Vaccine administered to 450 subjects on day 0 and 14
Group Type
ACTIVE_COMPARATOR
Shanchol Vaccine
Intervention Type
BIOLOGICAL
Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hillchol vaccine
HillChol®(BBV131) (Whole cell inactivated Stable Hikojima expressing both Inaba and Ogawa LPS) inactivated bacteria of a stable recombinant Vibrio cholerae O1 El Tor Hikojima serotype strain expressing approximately 50% each of Ogawa and Inaba O1 LPS antigens.
Intervention Type
BIOLOGICAL
Shanchol Vaccine
Shanchol™ (Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine)
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Participants /Legally acceptable representatives who have ability to provide written informed consent.
2. Participants of either gender of age \> 1 year.
3. Expressed interest and availability to fulfil the study requirements.
1. Willing to receive two dosesof the vaccine at the specific study site.
2. Willing to be contacted on the phone to assess adverse events and for study reminders.
4. Agrees not to participate in another clinical study at any time during the study period.
2. Participants of either gender of age \> 1 year.
3. Expressed interest and availability to fulfil the study requirements.
1. Willing to receive two dosesof the vaccine at the specific study site.
2. Willing to be contacted on the phone to assess adverse events and for study reminders.
4. Agrees not to participate in another clinical study at any time during the study period.
Exclusion Criteria
1. Any history of anaphylaxis in relation to vaccination.
2. Participant with Immune function disorders including immunodeficiency diseases, or taking immunosuppressive/cytotoxic agents.
3. An individual thought to have difficulty participating in the study due to severe chronic diseases, based on the judgment of the investigator
4. Participants with 38℃ or higher body temperature measured within 24 hours or at the time of investigational product dosing.
5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study initiation
6. Diarrhea or administration of anti-diarrheal drugs or antibiotics to treat diarrhea within 1 week prior to study initiation.
7. Other vaccination within 4week prior to study initiation.
8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation.
9. Participation in another clinical trial.
10. History of cholera vaccinations or history of cholera diarrhea.
11. Pregnancy, lactation or willingness/intention to become pregnant during the study.
12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
13. History of any psychiatric condition likely to affect participation in the study.
14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
15. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the study or would render the subject unable to comply with the protocol.
2. Participant with Immune function disorders including immunodeficiency diseases, or taking immunosuppressive/cytotoxic agents.
3. An individual thought to have difficulty participating in the study due to severe chronic diseases, based on the judgment of the investigator
4. Participants with 38℃ or higher body temperature measured within 24 hours or at the time of investigational product dosing.
5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study initiation
6. Diarrhea or administration of anti-diarrheal drugs or antibiotics to treat diarrhea within 1 week prior to study initiation.
7. Other vaccination within 4week prior to study initiation.
8. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation.
9. Participation in another clinical trial.
10. History of cholera vaccinations or history of cholera diarrhea.
11. Pregnancy, lactation or willingness/intention to become pregnant during the study.
12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
13. History of any psychiatric condition likely to affect participation in the study.
14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
15. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the study or would render the subject unable to comply with the protocol.
Minimum Eligible Age
1 Year
Maximum Eligible Age
99 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bharat Biotech International Limited
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King George Hospital,Visakhapatnam
Visakhapatnam, Andhra Pradesh, India
Site Status
All India Institute of Medical Sciences,Patna
Patna, Bihar, India
Site Status
Aatman Hospital
Ahmedabad, Gujarat, India
Site Status
Pt BD Sharma,PGIMS/UHS. Rohtak
Rohtak, Haryana, India
Site Status
Jeevan Rekha Hospital ,Belgaum
Belagavi, Karnataka, India
Site Status
Khalatkar Hospital, Nagpur
Nagpur, Maharashtra, India
Site Status
Redkar Hospital and Research center,Goa
Goa, South Goa, India
Site Status
Indus Hospital
Hyderabad, Telangana, India
Site Status
Rana Hospital Pvt Ltd ,Gorakhpur
Gorakhpur, Uttar Pradesh, India
Site Status
Prakhar Hopsital Pvt Ltd,Kanpur
Kanpur, Uttar Pradesh, India
Site Status
National Institute of Cholera and Enteric Diseases,Kolkata
Kolkata, West Bengal, India
Site Status
Countries
Review the countries where the study has at least one active or historical site.
India
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hillchol®BBV131/2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants
NCT00548054
UNKNOWN
PHASE2
Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine
NCT02742558
COMPLETED
PHASE2
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines
NCT01949675
COMPLETED
PHASE4
Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine
NCT00419133
COMPLETED
PHASE2
A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic
NCT02434822
COMPLETED
PHASE3
Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata
NCT00119197
COMPLETED
PHASE2
Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
NCT02532569
COMPLETED
PHASE4
Healthy Adult Volunteer Study for Two Doses of a Shigella Vaccine
NCT00210288
COMPLETED
PHASE2
Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
NCT06350058
ACTIVE_NOT_RECRUITING
PHASE1
Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata
NCT00289224
COMPLETED
PHASE3
A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers
NCT01091298
COMPLETED
PHASE1
Pilot Introduction of Oral Cholera Vaccine in Orissa, India
NCT01365442
COMPLETED
A Post-marketing Observational Study of Oral Cholera Vaccine
NCT07300462
NOT_YET_RECRUITING
PHASE4
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
NCT06615375
RECRUITING
PHASE2
Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults
NCT02669121
COMPLETED
PHASE2
Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi
NCT02499172
TERMINATED
NA
A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E
NCT01305109
UNKNOWN
PHASE3
Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
NCT04603131
COMPLETED
PHASE1
Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine
NCT01061658
UNKNOWN
PHASE1/PHASE2
Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects
NCT05805618
NOT_YET_RECRUITING
EARLY_PHASE1
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
NCT03220737
COMPLETED
PHASE4
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
NCT05349617
COMPLETED
PHASE3
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
NCT00757926
WITHDRAWN
PHASE1/PHASE2
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794
RECRUITING
PHASE3
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
NCT06314880
RECRUITING
PHASE1